Hyperuricemia in Chronic Kidney Disease: a role yet to be explained

Rui Barata, Filipa Cardoso, Tiago Assis Pereira
Department of Nephrology, Centro Hospitalar Universitário Lisboa Central, Hospital Curry Cabral, Lisbon, Portugal

ABSTRACT

The role of uric acid as an independent risk factor for chronic kidney disease development and progression is still a matter of discussion. Several observational studies showed a positive association between hyperuricemia and the progression of kidney dysfunction, but others did not, which probably derived from different biases and studies insufficiencies. Moreover, the results from studies on patients in hemodialysis and peritoneal dialysis are even more controversial, with some evidence pointing towards a protective role of uric acid in hemodialysis patients, but not in peritoneal dialysis. In addition to most evidence suggesting a role of uric acid in chronic kidney disease pathogenesis and progression, pharmacological treatment of asymptomatic hyperuricemia is still not indicated, with no consensus on either the uric acid level at which treatment would be beneficial, or the target-level to achieve. There are several studies on the renal benefits of xanthine oxidase inhibitors allopurinol and febuxostat, with heterogeneous results. Most of them showed a renoprotective effect of both drugs, delaying renal disease progression. However, the different results found in other studies makes it difficult to draw definitive conclusions. Despite recent evidence pointing toward an important role of uric acid in the pathogenesis and progression of kidney disorders, and the benefits of its treatment, there are still several unanswered questions, and well-conducted studies are needed to make valid conclusions.

Key-Words: Chronic Kidney Disease, Disease prevention, Urate lowering therapy, Uric acid, Xanthine oxidase inhibitors.
acid paradox. A possible explanation, derived primarily from animal studies, is that UA has different actions depending on the surrounding cells and chemical environment. In addition to the extracellular effects related to endothelial cells already described, intracellular UA exerts pro-oxidant effects: it reduces nitric oxide inside endothelial cells, stimulates vascular smooth muscle cells proliferation and promotes production of reactive oxygen species and insulin resistance in adipocytes.

DEFINITION OF HYPERURICEMIA

The definition of hyperuricemia is still debated, and there is no universal consensus. A practical answer is based on the UA solubility point at physiologic temperature and the pH, which is 6.8 mg/dl. However, many clinical trials have been using different cut-offs, with levels of UA >7 or 7.5 mg/dl in men and >6 or 6.5 mg/dl in women. In fact, the UA threshold for pathologic level is still controversial, as the levels in healthy population are very heterogeneous, and a large proportion of individuals with high levels of UA do not develop clinical manifestations of gout.

PATHOPHYSIOLOGY OF HYPERURICEMIA IN CKD

Hyperuricemia has been conceptually determined by two types of causes: overproduction and underexcretion of UA; however, there can be a combination of both mechanisms. Hyperuricemia rises in parallel with glomerular filtration rate (GFR) decline, and is present in about 40% of patients with CKD stages I to III and 70% of patients with CKD stage IV or stage V.

UA may be associated with CKD development and progression through several mechanisms, some of them crystal-independent: direct toxicity to the kidney; exacerbation of other risk factors for kidney disease, such as hypertension; or by being a marker of the severity of other risk factors, including those attributable to or associated with diabetes and the metabolic syndrome. Some experimental studies suggest that hyperuricemia induces renal injury through renal vasoconstriction mediated by endothelial dysfunction, activation of the renin-angiotensin system, afferent arteriolopathy, and epithelial-to-mesenchymal transition in renal tubular cells. Additionally, hyperuricemia increases renin activity, leading to the upregulation of angiotensin II and proliferation of vascular smooth muscle cells. This results in vascular wall thickening, which leads to lumen obliteration and hypoperfusion of the kidney, with tubulointerstitial inflammation and fibrosis, as well as arterial hypertension. Furthermore, preglomerular vasculopathy caused by hyperuricemia disturbs the autoregulatory response of afferent arterioles, prompting glomerular hypertension. Tubulointerstitial fibrosis can also be a result of a UA induced epithelial-to-mesenchymal transition in renal tubular cells. In fact, in animal models, administration of a uricase inhibitor to rats caused tubular dilatation, cortex atrophy and glomerulosclerosis. Recent evidence also confirms an important role of UA induced inflammation, both by the more known crystal-dependent mechanisms, but also by direct effect of soluble urate, through oxidative stress, proinflammatory signaling, autophagy and intracellular immunometabolic sensors.

ASSOCIATIONS BETWEEN HYPERURICEMIA AND CKD

Despite the vast evidence of an association between higher UA levels and several risk factors for CKD, there are still conflicting results in clinical studies, with several unanswered questions regarding the role of UA as a casual, compensatory or coincidental phenomenon in these patients.

Hyperuricemia CKD: risk factor or risk marker?

It has long been known that there is a strong association between serum UA (sUA) levels and hypertension. In a meta-analysis regarding this association, Grayson et al showed that hyperuricemia causes a 41% increase in the risk of developing hypertension, with this association more pronounced in women and a younger population. Although the mechanism for this association is not well understood, it is probably related to UA mediated activation of the renin-angiotensin system, suppression of nitric oxide and direct vascular damage (especially to the renal afferent arterioles).

UA has long been associated with renal disease. At first, based on studies that showed an increase in the incidence of hyperuricemia in parallel with the decline in GFR, it was considered only a marker of CKD, instead of a risk factor causing it. However, the association between hyperuricemia and CKD may not be simply a consequence of decrease excretion of UA, and there are several studies confirming the association between hyperuricemia and the development and progression of CKD. In a community-based cohort with 13,388 patients followed for 9 years, baseline sUA levels were associated with increased risk for CKD, with odds ratios (OR) of 1.07 (95% confidence interval – CI 1.01-1.14) per each increase of 1 mg/dl in sUA, in a GFR-based model, even after adjustment for possible confounding parameters.

In another prospective study with 21,475 individuals followed for 7 years, patients with slight to moderate elevation of sUA (7.0 to 8.9 mg/dl) were associated with a nearly doubled risk for kidney disease (OR 1.74, with 95% CI 1.45 to 2.09), and patients with very high sUA (≥9.0 mg/dl) were associated with a threefold risk for kidney disease (OR 3.12, with 95% confidence interval 2.29 to 4.25).

However, not every study regarding this issue confirmed the association between UA and incident of CKD and its progression. In a study with 227 patients followed for 7 years, with CKD of non-diabetic etiology, there was no relationship between sUA levels and kidney disease progression when the analysis was adjusted for baseline kidney function parameters. In the MDRD study (Modification of Diet in Renal Disease), with 838 patients with CKD stages 3-4 followed for 10 years, the results showed a positive association of hyperuricemia with all-cause and cardiovascular mortality, but not with kidney failure (HR 1.02, with 95% CI 0.97 to 1.07). Thus, some claim that hyperuricemia is just an epiphenomenon of CKD, but not an independent risk factor.

Hyperuricemia in dialysis patients

Serum UA levels vary greatly in dialysis patients, whether hemodialysis (HD) or peritoneal dialysis (PD). In HD patients, the mean...
reported level of UA is 7.7 mg/dL (standard deviation of 1.4)\(^26\), whereas in PD patients the mean level of UA is 8.5 mg/dL (standard deviation of 2.1)\(^27\). However, these levels are highly variable between studies, and need careful interpretation, since UA levels in patients receiving dialysis depend on several factors, such as the dialysis prescription or the timing of the sample collection.

In HD, UA clearance is similar to urea\(^28\), since UA easily diffuses into the dialysate effluent. In an HD session with a standard prescription, the single pooled UA removal ration is 60-70% with high-flux dialyzers\(^29\). UA clearance for PD is 10-20 mL/min, being directly proportional to the dialysate exchange volume and flow rate\(^30\), and there seems to be no difference between automated and continuous ambulatory PD\(^31\).

The relationship between UA and mortality in dialysis patients has been evaluated in several studies, summarized by Murea and Tucker in a recent review\(^32\), which included 14 studies of patients on HD, and five studies in patients on PD. Regarding patients on HD, nine of the fourteen studies found an inverse association between UA and all-cause mortality. In one of those studies (n = 5827), Latif et al found that higher UA level were associated with lower all-cause mortality, with an hazard ration of 0.95 per 1 mg/dl higher UA level\(^32\). However, five of those studies found either no association or a direct association between UA and mortality. As for PD, two of those studies found a direct association between UA and mortality, while the other three studies found none.

There are important differences in the results among those studies, which can be a consequence of several biases. However, there seems to be an important difference between both dialysis techniques, since the inverse association of higher UA levels and lower mortality was specific only for HD. Although there is no clear explanation for these results, there are some hypotheses suggested. Some advocate that higher sUA levels are associated with less mortality because sUA is a marker of better nutrition. However, some studies showed that, even after adjustment for nutritional parameters, there was still an association between sUA and mortality. In one of those studies\(^32\), a prospective study with 261 patients on HD, the authors demonstrated an association between higher levels of sUA and a lower hazard ratio\(^32\). However, five of those studies found either no association or a direct association between UA and mortality. As for PD, two of those studies found a direct association between UA and mortality, while the other three studies found none.

Another explanation for these results relies on the timing of measurement of sUA levels in HD patients. Given that UA is dialysed in a similar way to urea, levels will fluctuate greatly between HD sessions, and the pre-HD concentration does not reflect the mean levels in those patients. Some studies show that after a HD session, sUA levels tend to decrease by 64.6%\(^34\), which means that, between two sessions, those patients will have sUA between those levels. Thus, a patient with normal or low sUA before HD would have a much lower weekly time-averaged mean sUA, with levels probably lower than the necessary concentration for UA to execute its normal antioxidant functions. Likewise, patients with high sUA levels before HD would have near-normal mean sUA levels weekly time-averaged\(^10\). Although this is an unconfirmed hypothesis, it could explain the protective effects of higher pre-HD sUA levels, and the difference between HD and PD patients.

Hyperuricemia in transplant patients

Hyperuricemia is frequent in renal transplant patients, normally occurring early in the post-transplant period\(^25\). Frequent risk factors for hyperuricemia in these patients include the use of calcineurin inhibitors (cyclosporine being the most common risk factor for hyperuricemia in the post-transplant period\(^25\)) or diuretics, reduced glomerular filtration rate (GFR), obesity, recipient age and pre-existing history of hyperuricemia\(^36\).

However, the evidence regarding the effects of hyperuricemia on renal allograft function and survival is very heterogeneous and inconclusive\(^37\). Some studies showed an inverse association between hyperuricemia and renal allograft function and survival\(^38-40\), suggesting a role for hyperuricemia as an independent risk factor. However, this association is not evident in other studies, which conclude that sUA is merely a marker of graft dysfunction\(^41-43\).

The evidence regarding treatment of asymptomatic hyperuricemia is also controversial. However, lifestyle measures and avoidance of cyclosporine and diuretics are acceptable strategies to reduce sUA levels\(^36\).

TREATMENT OF HYPERURICEMIA IN CKD

General principles

As a result of the lack of strong evidence regarding the role of hyperuricemia in patients without gout or nephrolithiasis, current guidelines do not support the treatment of isolated hyperuricemia with urate lowering therapy. However, advice on lifestyle and the treatment of associated comorbidities is always advised\(^44\).

Despite the limited effect of lifestyle modification on sUA and the lack of evidence from RCTs, every patient with hyperuricemia should receive appropriate advice on lifestyle recommendations to lower sUA. Furthermore, most of these measures are useful in the vast majority of the comorbidities that patients with hyperuricemia frequently have\(^45\). However, given their limited effect, they should be considered an adjunctive, and should not replace pharmacologic treatment, whenever indicated\(^46\). Those measures include:

- Reduce weight and daily exercise, even though the effects are only modest (losing 7.7 kg decreases, in average, 1.6 mg/dL in sUA)\(^47\);
- Decrease consumption of purine-rich meat and seafood;
- Reduce energy drinks and soft drinks sweetened with fructose corn syrup\(^45\);
- Limit the intake of beer, wine and spirits\(^46\);
- Minimize the use of drugs that increase sUA, such as diuretics, beta-blockers or low dose of acetylsalicylic acid\(^3\).


**Urate-lowering agents**

There are 3 main classes of urate-lowering agents: uricosuric agents, which increase kidney UA excretion; xanthine oxidase inhibitors (allopurinol and febuxostat), which block the conversion of purine metabolites to UA; and recombinant uricases, which oxidize UA into a highly soluble product.

**Allopurinol**

Allopurinol is a xanthine oxidase inhibitor, and it is metabolized into oxypurinol, which is excreted by the kidneys. For this reason, and since allopurinol may cause hypersensitive reactions, its dose must be reduced in patients with CKD. In patients with an eGFR <60 mL/min/1.73m², it is recommended to start at a dose of 50-100 mg/day, increasing the dose to 200 or 300 mg/day after 2-5 weeks to achieve serum UA levels of <6 mg/dL. It is acceptable to use doses >300 mg/day, as long as there is proper monitoring of toxicity. Its main adverse events are related to allopurinol hypersensitivity syndrome, characterized by skin rash, eosinophilia, hepatitis and fever, a rare but potentially life-threatening condition.

There is generally a scarcity of RCT regarding effects of control of hyperuricemia in CKD patients. In a 2013 systematic review of 8 RCT, Bose et al compared treatment of hyperuricemia with versus placebo and its effect on the retardation of CKD. In 5 of these studies, they found no significant differences in eGFR among patients in each group. The other 3 trials showed a slight benefit on the allopurinol arm, but no significant changes in proteinuria or blood pressure. However, there was an important heterogeneity in the monitoring of kidney function and the follow-up among these studies.

In another meta-analysis which included 19 RCTs, Kanji et al found significant benefits with allopurinol therapy in terms of reducing serum UA levels, blood pressure control and a slight improvement in eGFR.

**Febuxostat**

Febuxostat is a newer xanthine oxidase inhibitor, with more efficacy and specificity than allopurinol for xanthine oxidase. Its elimination is mainly by the liver and bile, and it is less associated with hypersensitivity than allopurinol. Its main adverse effects include liver function abnormalities, diarrhea and rash. It should not be used simultaneously with azathioprine or mercaptopurine, since those drugs are metabolized by xanthine oxidase and their levels may increase, causing toxicity. Regarding its safety in renal disease, it can be used without dose reduction in patients with eGFR ≥30 mL/min. However, most of the safety studies included only a few patients with CKD stages 2-4, and the studies in patients on dialysis are even fewer, which is why the FDA has not yet approved febuxostat in that population. Other than that, it appears to be well tolerated and efficient. Thus, it should be used with dose reduction in patients with CKD stages 4-5.

In spite of being a newer drug than allopurinol, there are already several published studies demonstrating its beneficial effects on renal function. In a post-hoc analysis of the FOCUS (Febuxostat Open-label Clinical trial of Urate-lowering efficacy and Safety) study, with 116 hyperuricemic gout patients receiving febuxostat at different doses (40, 80, or 120 mg) for 5 years, there was a clear benefit on renal function, with maintenance (or even improvement) in eGFR that was inversely correlated with the amount of reduction in sUA, with an expected improvement in eGFR of 1 mL/min for every 1 mg/dL reduction in sUA.

In the EXCEL (Febuxostat/Allopurinol Comparative Extension Long-Term) study (n=1086), patients were treated with either febuxostat (80 or 120 mg daily) or allopurinol (300 mg daily). The febuxostat group showed significant benefits of renal function, with greater reductions in sUA associated with less decline in renal function (preservation of 1.2 mL/min/1.73 m² for every 1 mg/dL reduction in sUA).

However, some studies failed to show beneficial renal outcomes with febuxostat. More recently, a randomized trial with 467 patients with stage 3 CKD, receiving either placebo or febuxostat, showed no significant difference in renal function within the febuxostat, with similar mean eGFR slopes between both groups.

There are several ongoing trials regarding the effects of urate-lowering therapy with febuxostat, as conclusive evidence is needed.

**Other pharmacological agents**

Uricosuric agents include benzbromarone, lesinurad, probenecid and sulfinpyrazone. Despite being effective in reducing sUA in patients with normal kidney function, their use is limited in CKD patients, being contraindicated for stage IV CKD (lesinurad is contraindicated if creatinine clearance <45 mL/min), including dialysis patients. The evidence regarding their benefit on slowing renal dysfunction is scarce, but there are some studies running regarding this issue. Also, their use must be avoided in patients with past history of nephrolithiasis, and are contraindicated in patients with uricosuria greater that 700 to 800 mg/24h. Further, there are some issues concerning their safety, with lesinurad being associated with acute kidney injury when used alone (which is the reason it needs to be co-prescribed with a xanthine oxidase inhibitor), and benzbromarone being associated with hepatotoxicity.

Other drugs commonly used for other medical indications but with uricosuric properties include losartan, fenofibrate, SGLT2 inhibitors, vitamin C and high doses of acetalsalicylic acid.

Pegloticase, a recombinant uricase, is approved for use in patients with gout that is refractory to oral agents for hyperuricemia. It is administered intravenously, and can be used in patients with advanced CKD and dialysis patients. Rasburicase is another recombinant uricase which is approved for use in patients with malignancies receiving chemotherapy, when tumor lysis syndrome is expected.

**CONCLUSION**

The association between hyperuricemia and CKD has long been known. However, although many observational studies have identified associations between hyperuricemia and the onset and progression of CKD, there is currently a scarcity of RCT and meta-analyses regarding its effect on slowing renal function. Further, there is a need for randomized trials regarding the long-term effects of urate-lowering therapy with febuxostat, as conclusive evidence is needed.
CKD, some have not. Thus, although much evidence points toward a role of sUA in the pathogenesis of CKD, the current evidence cannot conclude for certain that it is not just a marker of kidney dysfunction. Regarding treatment of hyperuricemia, and as a consequence of the heterogeneous evidence on the role of UA in CKD, there is still no indication for treating asymptomatic patients. Although there are several observational studies evaluating the effect of urate lowering therapy on the development and progression of CKD, the results are heterogeneous, much derived from several biases, including the small number of patients included in much of them, and the short follow-up. For more clear and accurate results, large randomized controlled trials are needed. Besides that, there are still some doubts on whether the renoprotective effects of allopurinol and febuxostat found in some studies are related to their effect on sUA levels, or to their xanthine oxidase inhibition. Another question yet to be answered is the sUA level at which pharmacological therapeutic must be started, and the optimal target level to slow CKD progression.

Concluding, although there are already some insights into the role of hyperuricemia in CKD, and the potential renoprotective effects of urate lowering therapy, the current evidence is still not strong enough to make valid conclusions, and well-conducted studies are needed.

**Disclosure of potential conflicts of interest:** none declared

**References**

1. Boddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am. 2014;40(2):155-175.
2. Edwards NL. The role of hyperuricemia and gout. Cleveld Clin. J Med. Vol. 2008;13:6-12.
3. Borghi C, Rosse EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2018;35(11):2175–2178.
4. Wu X, Muzy D, Chis Lee C, Thomas Casley C. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34(1):78-94.
5. Mallat SG, Al Kattar S, Tanios BY, Jurjus A. Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr Hypertens Rep. 2016;18(10).
6. Calabrese R, Napoli P, Kurella T, Inzucchi SE, Sesso HD, Varigos JA, et al. Uric acid levels and renal function in adult renal transplant recipients: evidence from the symposium. J Am Soc Nephrol. 2009;20(4):1571-1580.
7. Boratynska M, Karbowska A, Klinger M. The effect of hyperuricemia on endothelial biomarkers and renal function in renal transplant recipients. Transplant Proc. 2017;49(12):4074-4077.
8. Madeiro M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2014;54(2):90-98.
9. Kangan T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16(1).
10. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, et al. Selectivity of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in healthy male subjects. J Pharm Pharmacol. 2011;63(9):1351-1359.
11. Madeiro M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2014;54(2):90-98.
12. Madeiro M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2014;54(2):90-98.
13. Madeiro M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2014;54(2):90-98.
14. Madeiro M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2014;54(2):90-98.
15. Madeiro M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2014;54(2):90-98.
16. Madeiro M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2014;54(2):90-98.
17. Madeiro M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2014;54(2):90-98.
Hyperuricemia in Chronic Kidney Disease: a role yet to be explained

54. Kathleen J, Orcid L. Accepted article. J Subst Abuse Treat. 1996;13(3):287-288.
55. Lim DH, Oh JS, Ahn SM, Hong S, Kim YG, Lee CK, et al. Febuxostat in hyperuricemic patients with advanced CKD. Am J Kidney Dis. 2016;68(5):819-821.
56. Horikoshi R, Akimoto T, Inoue M, Morishita Y, Kuano E. Febuxostat for hyperuricemia: experience with patients on chronic hemodialysis treatment. Clin Exp Nephrol. 2013;17(1):149-150.
57. Whelton A, MacDonald PA, Zhao L, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17(1):7-13.
58. Whelton A, MacDonald PA, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013;125(1):106-114.
59. Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798-810.

60. Kydd ASR, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014;2014(11).
61. Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opin Drug Saf. 2019;18(4):261-271.

Correspondence to:
Rui Barata, MD.
Department of Nephrology, Centro Hospitalar Universitário Lisboa Central
Rua da Beneficência 8, 1069-166 Lisbon, Portugal.
E-mail: rui.f.barata@gmail.com